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Estrogens play an essential role in the normal physiology of the breast as well as in mammary tumorigenesis. Their eﬀects
are mediated by two nuclear estrogen receptors, ERα and β, which regulate transcription of speciﬁc genes by interacting with
multiprotein complexes, including histone deacetylases (HDACs). During the past few years, HDACs have raised great interest as
therapeutictargetsintheﬁeldofcancertherapy.Inbreastcancer,severalexperimentalargumentssuggestthatHDACsareinvolved
at multiple levels in mammary tumorigenesis: their expression is deregulated in breast tumors; they interfere with ER signaling in
intricate ways, restoring hormone sensitivity in models of estrogen resistance, and they clinically represent new potential targets
for HDACs inhibitors (HDIs) in combination with hormonal therapies. In this paper, we will describe these diﬀerent aspects and
underline the clinical interest of HDIs in the context of breast cancer resistance to hormone therapies (HTs).
1.Introduction
1.1. Breast Cancer and Hormonal Therapies. Breast cancer is
themostcommonmalignancyandthesecondmostcommon
cause of cancer-related death amongst women in France,
Western Europe and North America. About 70% to 80%
of inﬁltrating breast carcinoma are estrogen receptor alpha
(ERα) positive, thus oﬀering clinicians the opportunity of
hormonal therapies (HTs) in adjuvant and/or metastatic
situation. Modulation of estrogen signaling pathways using
antiestrogens (such as Tamoxifen or Fulvestrant) or more
recently aromatase inhibitors (such as Exemestane, Letro-
zole, or Anastrozole) was indeed one of the ﬁrst recognized
targeted therapies and is currently the ﬁrst-line treatment for
ERα positive tumors [1]. The eﬀectiveness of HTs is directly
linked to the expression and functionality of ERα.S e v e r a l
retrospective studies and clinical trials have demonstrated
that tumors expressing both ERα and progesterone receptor
(PR) respond signiﬁcantly better to HTs than those with
low receptor expression [2, 3]. Among patients who have
a tumor expressing both ERα and PR, a beneﬁt from HTs
is seen in about 60% of cases, but the initial response
is often not durable, since tumors become resistant to
hormonal manipulation, leading to an “endocrine-resistant
disease”. Moreover, patients with breast carcinoma lacking
ERα (ERα negative) will not beneﬁt from these therapies, as
the expected eﬃciency of HTs in this situation is less than
10%.
Deﬁnition of the speciﬁc genetic lesions and molecular
processes that determine clinical endocrine resistance is still
incomplete. Candidate molecular pathways of intrinsic and
acquired resistance to HTs emphasize the importance of
signaling networks which control cell proliferation (e.g.,
actingviaepidermalgrowthfactorreceptortype2(HER2)or
insulin-like growth factor-1 receptor (IGF-1R)) or survival
(through molecules such as Bad or Bcl-2) [4, 5]. In addition,
polymorphisms in metabolizing enzymes such as the hepatic
drug-metabolizing cytochrome P450 2D6 (CYP2D6) may2 Journal of Biomedicine and Biotechnology
reduce the therapeutic beneﬁt from tamoxifen (for a review,
see [6]). Today, the main challenges in mammary cancer
research are thus the development of more speciﬁc biomark-
ers to predict response or resistance to hormonal therapy
and the development of new combined targeted therapies of
hormone therapy-insensitive or therapy-resistant tumors.
1.2. Nuclear ER Signaling. Estrogens, like many other hor-
mones, elicit numerous biological responses. They play a
major role in the development and maintenance of the
female reproductive tract (including the mammary glands)
and are also involved in breast tumorigenesis. They act on
target tissues through binding to two ER isoforms (ERα and
ERβ), which are members of the nuclear hormone receptor
(NR) superfamily [7]. Upon interaction with ERs, estrogens
induce a conformational change, which favors receptor
dimerization and recruitment to promoter elements either
directly through their DNA-binding domain or indirectly
through interaction with other transcription factors. ER
complexes then recruit transcriptional coregulators (coacti-
vators and corepressors) to increase or inhibit target gene
transcription [7]. In most cases, transcriptional cofactors are
recruited as multiprotein complexes that could act either
sequentially or simultaneously, depending on the considered
gene. Many transcriptional coregulators of NRs exhibit
enzymatic activities that participate in their mechanism of
action. For example, several coactivators—CBP/p300, pCAF,
SRC-1, and SRC-3—are acetyltransferases that are able to
modify various lysine residues located in the amino terminal
tails of histones. Conversely, inhibitory complexes associated
with corepressors, contain histone deacetylases (HDACs)
whose activity counteracts that of acetyltransferases (HATs).
Some other enzymatic activities—including kinases or
methyltransferases—displayed by coregulators are also able
to modify histone lysines, arginines, or serines. All these
posttranslationalmodiﬁcationsinterferewitheachotherand
represent signals that enable binding of proteins involved in
thetranscriptionalcontrolofgeneexpression.Fromaclinical
point of view, transcription therapies targeting pathological
epigenetic modiﬁcations are very promising approaches to
improve cancer treatment (see below).
2.HistoneDeacetylasesandInhibitors
2.1. Acetylation of Chromatin and Nonchromatin Proteins.
Acetylation and deacetylation of the ε-amino group of Lys
residue(Nε)isareversiblereactioncatalysedbytheopposing
actions of Lys acetyltransferases and Lys deacetylases. This
modiﬁcation, also described in bacteria, has been ﬁrst
extensively studied in the context of chromatin and histone
modiﬁcations. As noted above, acetylation and deacetylation
of the N-terminal tails of histones contribute to the “histone
code”whichdeﬁnespartoftheepigeneticlandscapeinvolved
in the regulation of gene expression. It is now known that in
additiontohistonesandtranscriptionfactors,Nε-acetylation
target numerous other proteins, such as proteins involved in
cell signaling, DNA repair, metabolism, apoptosis, cytoskele-
ton, and protein folding (see also Section 5 of this paper).
N acetyl Lysine may serve as a docking structure for bro-
modomain,aproteindomainthathastheabilitytorecognize
acetyl-lysine motifs. Nε-acetylation may either enhance or
decrease the function of the protein targeted, depending on
the presence of other posttranslational modiﬁcations on the
protein (such as phosphorylation and methylation) and the
eﬀects of Nε-acetylation on protein/protein interactions [8].
Although both enzymes are involved in the modulation
of protein acetylation, HDACs have been extensively studied
as therapeutic targets, in particular in the context of cancer,
while few studies have been performed on the clinical
beneﬁts of regulating HATs.
2.2. The HDAC Family. Up to now, eighteen human HDACs
have been identiﬁed. They are divided into 4 families
according to sequence homologies: class I (HDAC1, -2,
-3, and -8) and class II (HDAC4, -5, -6, -7, -9, and -10)
are homologous to the yeast histone deacetylases Rpd3
and Hda1, respectively, and share some degree of sequence
homology. Class IV HDAC11 has been discovered more
recently and shows similarities to both yeast Rpd3 and Hda1.
Class I, II, and IV enzymes present a zinc ion-dependent
catalytic domain. By contrast, class III enzymes (called
sirtuins) are homologous to the yeast protein Sir2 and use
NAD as a cofactor [9].
In the past few years, the crystal structure of the catalytic
domain of human class I HDAC8 and class II HDAC4 and
HDAC7 has been elucidated and several knockout mice tar-
geting various HDACs have been generated, thus providing
insights into their structure and physiological functions [10–
13]. The diversity of HDACs suggests diﬀerential roles for
the various classes of enzymes depending on tissues or cell
lines. Accordingly, HDACs have been linked to cell cycle and
proliferation and to the diﬀerentiation of various tissues.
In addition to these physiological roles, the HDAC family
has been involved in the physiopathology of human diseases
including cancer. Fusion proteins containing HDACs com-
plexes as well as deregulation of protein acetylation and/
or HDACs expression have indeed been shown for various
hematopoietic or solid tumors [14, 15]. Such ﬁndings have
long encouraged the development of HDAC inhibitors as
anticancer agents.
2.3. HDAC Inhibitors. Sodium butyrate (NaBu) was the
ﬁrst HDAC inhibitor (HDI) to be discovered in the late
seventies, being initially found to have antitumor activity by
inducing cell diﬀerentiation. Since then, various HDIs with
diﬀerent structures and potencies have been synthesized or
puriﬁed from natural sources, and their eﬀects as anticancer
drugs are now widely documented. In 2006, suberoylanilide
hydroxamic acid (SAHA or Vorinostat) was the ﬁrst HDI
approved by the FDA for the treatment of cutaneous T-cell
lymphoma [16]. Today, the development of HDIs for the
treatment of cancer is still ongoing and 80 phases I and II
clinical trials are currently underway to validate these drugs
alone or in association with other therapies in patients with
hematological or solid tumors (see Section 6)[ 17, 18].
Diﬀerent studies using cDNA array approaches have
shown that around 10% of genes are modulated by HDIs,Journal of Biomedicine and Biotechnology 3
with diﬀerences in the genes altered linked to the cell model,
the time of culture, the concentration, and the HDIs used
[19, 20]. Nevertheless, HDIs have been shown to have potent
antitumor eﬀects in vitro and in vivo on various cancer
types aﬀecting tumor cells at multiple levels: induction of
cell cycle arrest, apoptosis and diﬀerentiation, inhibition of
angiogenesis, inhibition of cell migration and invasion, and
increase in antitumor immunity, response to radio- and
chemotherapies (for reviews see [14, 21, 22]).
One of the challenges for the next years will be the
development of more selective HDIs that would target
speciﬁc HDAC isoforms to oﬀer the patients the best
therapeutic responses with the lowest toxicity. Speciﬁc HDIs
have thus been described targeting class I HDACs and class
II HDACs or HDAC8, some of them being tested in clinical
trials, such as class I-speciﬁc MGCD0103 (Mocetinostat)
in Hodgkin lymphoma [23]. Another challenge will be
to search for biomarkers of clinical response to HDIs
[24]. Some biomarkers have already been proposed such
as histone H3 and H4 acetylation in tissues or peripheral
blood mononuclear cells, HDAC2 tissue expression [25],
gene expression proﬁles [26], or more recently expression of
HR23B, a protein involved in the targeting of ubiquitinylated
proteinstotheproteasome[27].Despiteencouragingresults,
the identiﬁcation of potential biomarkers of response to
HDIs is critically needed for future trials that will combine
these drugs with endocrine therapy.
3. HDACsand Breast Cancer
3.1. HDAC Expression in Breast Cancers. HDAC expression
in breast tumors has not been described for all members of
the HDAC family, but mostly concerns class I HDAC1, -2,
and -3 and class IIb HDAC6 at the protein and/or mRNA
levels. Analysis of their prognostic signiﬁcance in breast
carcinoma has been performed in some studies (see below
and [15]f o rar e v i e w ) .
Regarding mammary tumor progression, Suzuki et al.
[28] reported a marked reduction in histone acetylation
from normal mammary epithelium to ductal carcinoma
in situ (DCIS) whereas most cases showed similar levels
of acetylation in DCIS as compared to invasive ductal
carcinoma. This suggests that alterations of histone acety-
lation are an early event in breast tumor progression. The
authors also described a signiﬁcant but smaller decrease in
HDAC1, HDAC2, and HDAC6 protein levels during tumor
progression. Greater reductions in HDAC1 protein levels
were observed from normal to DCIS in estrogen-receptor
negative and high-grade breast tumors (Table 1). According
to the authors, such discrepancy (i.e., concomitant decrease
inHDACexpressionandhistoneacetylation)couldbelinked
to the relative activities of both HATs and HDACs, as altered
expression of HATs has been described in various cancers.
It is also possible that the expression of other HDACs, not
analyzed in this study, is increased during breast cancer
progression, thus encountering for the global reduction in
histone acetylation.
Analyzing invasive breast carcinoma, Krusche et al.
detected HDAC1 protein expression in the nucleus of
Table 1: Expression of HDACs in relation with ER.
HDAC HDAC expression References
HDAC1 Reduced expression from
normal to DCIS (ER- tumors) [28]
Correlation with ER
expression [29]
High level of mRNA in ER+
breast cancers [30]
HDAC2 Locus deletion in ER+ PR+
breast cancers [31]
Underexpressed in ER+ breast
cancers [32–55]∗
HDAC3 Overexpressed in ER+ breast
cancers [44]∗
Correlation with ER
expression [29]
Underexpressed in ER+ breast
cancer [56]∗
HDAC4 Overexpressed in ER+ breast
cancers [45, 47]∗
Underexpressed in ER+ breast
cancers [38, 43, 53, 54, 57]∗
HDAC5 Overexpressed in ER+ breast
cancers
[34, 37, 39, 51, 52, 54,
57, 58]∗
HDAC6 Overexpressed in ER+ breast
cancers [45, 47, 51, 53]∗
High level of mRNA in ER+
breast cancer [59]
Increased expression in ER+
breast cancer [60]
Underexpressed in ER+ breast
cancers [32, 34, 37, 50–52]∗
HDAC7 Overexpressed in ER+ breast
cancers
[36–38, 40, 44, 45, 47,
53, 58, 61]∗
HDAC8 Underexpressed in ER+ breast
cancers [45, 47, 56, 62]∗
HDAC9 Underexpressed in ER+ breast
cancers
[32, 34, 35, 37–
40,45,47,52–54,58]∗
HDAC10 Overexpressed in ER+ ductal
breast cancer [48]∗
HDAC11 Overexpressed in ER+ breast
cancers
[35, 37–
40, 43, 45, 47, 51–
53, 56, 58]∗
SIRT1 Overexpressed in ER+ breast
cancers [38, 40, 46, 52, 53]∗
References with ∗ were obtained from the Oncomine database. Increased or
decreased expression was considered statistically signiﬁcant at P<. 05.
mammary luminal epithelial cells, but not in basal cells,
a n do b s e r v e dt h ep r e s e n c eo fn u c l e a rH D A C 1a n dH D A C 3
proteins in 40% and 44% of breast tumors, respectively.
They also found that HDAC1 and 3 protein levels corre-
lated signiﬁcantly with estrogen and progesterone receptors
expression and that HDAC1 was an independent prognostic
marker of better disease-free survival (DFS), but not overall
survival (OS) in patients with invasive breast carcinoma4 Journal of Biomedicine and Biotechnology
[29]. Similarly, Zhang et al. analyzed HDAC1 mRNA levels
in invasive breast tumors and showed that HDAC1 mRNA
levels were elevated in ER and PR positive tumors. They also
found that patients with breast tumors displaying high levels
of HDAC1 mRNA levels tended to have a better prognosis;
however, in this study, HDAC1 was not found to be an
independent prognostic marker of either DFS or OS [59].
Several studies have focused on HDAC6 expression in
breast carcinoma. The rational for such studies relies on
initial results showing that HDAC6 was as an estrogen-
responsive gene identiﬁed by a microarray approach and
that it could modulate mammary tumor cell motility in
vitro [60, 63]. More recently, Lee et al. also showed that
HDAC6 was required for anchorage-independent growth of
breast tumor cells [64]. HDAC6 protein was detected in 65%
[59] and 77% [60] of breast carcinoma, with a cytoplasmic
localization of the protein in both studies. Higher levels of
HDAC6 mRNA were found in small, low-grade and ER+,
PR+ breast tumors, that is, tumors of better prognosis, but
this result was not conﬁrmed at the protein level [59]. When
analyzing the diﬀerent studies, the prognosis signiﬁcance
of HDAC6 expression in invasive breast carcinoma remains
controversial [15]. For instance, Yoshida et al. found that
high levels of HDAC6 correlated with a negative prognosis
survival whereas Zhang et al. showed that high levels of
HDAC6 mRNA and protein was linked to improved DFS
but not OS [59, 65]. On the other hand, Saji et al. did
not link HDAC6 expression to DFS or OS, but found
increasedexpressionofHDAC6inasubgroupofER-positive,
tamoxifen-responsive breast carcinoma.
Fewer studies have been performed on HDAC2 in breast
carcinoma although its expression is frequently altered in
cancer [14, 15]. I nar e c e n ta n a l y s i so fg e n e t i ca l t e r a t i o n s
associated with breast cancer subtypes, Hu et al. found dele-
tions/lossoftheHDAC2locusinER-positiveandPR-positive
breast tumors, but no data on HDAC2 expression were
presented in this study [31]. HDAC2 mutations resulting in
loss of HDAC2 protein and resistance to apoptosis induced
by HDIs have been described in colon cancer [66]. However,
to our knowledge, no mutations in HDAC2 or any other
HDACs have been described in breast cancer.
In addition to these published data, we have performed
data mining on HDAC expression in breast cancer using
the Oncomine database (Compendia Bioscience, Ann Arbor,
MI, USA-www.oncomine.org/). As shown in Table 2, the
expression of some HDACs appears to be deregulated in
breast cancers as compared to normal breast tissues. This is
particularly true for HDAC2 and HDAC11 (overexpressed
in cancer) or HDAC4–6 and the class III enzyme SIRT1
(underexpressed in cancer). In addition, the same data
mining approach reveals that the expression of HDAC3–7,
10, 11, and SIRT1 at the mRNA level is higher in ER-positive
breast cancers (Table 1).
In conclusion, although careful analysis of their expres-
sion and consequences in breast cancer have not already
been performed for all members of the HDAC family, several
studies and Oncomine data analysis underline the potential
role of HDAC deregulation in breast tumor progression.
Table 2: Expression of HDACs in breast cancers.
Enzyme
(locus) Total studies Increased
expression in BC
Decreased
expression in BC
HDAC1
(1p34) 51 1
HDAC2
(6q21) 7 5 2
HDAC3
(5q31) 51 2
HDAC4
(2q37.3) 61 5
HDAC5
(17q21) 51 4
HDAC6
(Xp11.23) 80 3
HDAC7
(12q13.1) 50 1
HDAC8
(Xq13) 52 1
HDAC9
(7p21.1) 64 2
HDAC10
(22q13.31) 80 1
HDAC11
(3p25.1) 6 3 1
SIRT1
(10q21.3) 90 3
From Oncomine database (Compendia Bioscience, Ann Arbor, MI, USA-
www.oncomine.org/). Diﬀerential expression in breast cancer (BC) versus
normal breast tissue was considered signiﬁcant at P<. 05. Bold numbers
correspond to the strongest deregulations.
3.2. Eﬀects of HDI on Breast Cancers—Experimental Data.
In breast tumor models, HDIs have potent antiproliferative
eﬀects in vitro and in vivo and interfere with estrogen
signaling regulating ERα and ERβ expression and function
(see Section 4 and 5).
VariousHDIhavebeenshowntoinhibittheproliferation
of breast tumor cell lines, as well as normal human breast
epithelial cells with IC50 ranging from nM to few mM
depending on the HDIs tested [67–69]. This antiproliferative
eﬀe c tw a sf o u n dt ob em o r ep r o n o u n c e di nE Rp o s i t i v e
breast tumor cells than in ER negative ones [70, 71]. In
various tumor models, this eﬀect was in part linked to the
induction of the cell cycle inhibitor p21 by HDI [70, 72].
Interestingly, p21 gene was found to more sensitive to HDI
in ER positive than in ER negative mammary tumor cells,
which may explain the observed diﬀerence in inhibition of
cell proliferation upon HDI treatment according to the ER
status [70]. Moreover, HDI were found to decrease Cyclin
D1 expression and stability in mammary tumor cells and
to inhibit phosphorylation of the retinoblastoma protein
[71, 73–76]. Depending on the cell model, modiﬁcations of
other cell cycle regulators have also been described including
p27andcyclinB1[76,77].Accordingly,HDIinducecellcycle
blockade at the G0-G1 and/or the G2/M level [74, 76–79].Journal of Biomedicine and Biotechnology 5
Table 3: HDACs and estrogen signaling.
HDAC Eﬀect on estrogen signaling References
HDAC1 Recruited to the silenced ERα promoter [80]
Present on ER-target gene promoter region [81]
Knockdown reduces ERα levels [82]
Directly interact with ERα-suppresses ERα
activity in 293T cells
[83]
HDAC2 Present on ER-target gene promoter region [84]
Knockdown reduces ERα levels [82]
HDAC3 Present on ER-target gene promoter region [81]
HDAC4 Present on ER-target gene promoter region [85]
Binds the N-terminal A/B domain of ERα [86]
HDAC5 Repress ERα promoter via MEF2 [87]
Directly interacts with ERα-Represses ERα
activity
KO associated with upregulation of ERα
signaling
HDAC6 Knockdown reduces ERα levels [82]
Bind the AF2-domain of ERα [88]
Regulates ERα degradation via hsp90
acetylation
[89]
HDAC7 Present on the pS2 gene promoter region [84]
Represses ERα activity-Required for
E2-dependent repression
[90]
HDAC9 Repress ERα promoter via MEF2 [87]
Directly interacts with ERα-Represses ERα
activity
KO associated with upregulation of ERα
signaling
SIRT1 Deacetylates ERα in vitro
Knockdown reduces ERα levels [91]
Most of these studies have been performed using HDI
of broad range speciﬁcity. Recently, Duong et al. showed
that inhibition of class II HDACs, using speciﬁc chemical
compounds, also led to inhibition of mammary tumor
cells proliferation in a dose-dependent manner, with higher
potency in ER-positive than in ER-negative cell lines. In
this study, speciﬁc inhibition of class II HDACs induced
p21 expression, leading a cell-cycle blockade at the G0-G1
level [74]. Thus, although class II HDACs have been linked
to cell diﬀerentiation, they may also be involved in cell
proliferation, at least in this tumor model.
In vitro, HDI were found to induce apoptosis in breast
tumor cells expressing or not ERα [74, 77, 92]. Depending
on the cell type and/or the HDI used, apoptosis was linked
to activation of the intrinsic (mitochondrial) and/or the
extrinsic pathway. Some studies have shown upregulation
of the proapoptotic Bak and Bim members along with a
downregulation of the antiapoptotic survivin, XIAP and
Bcl2 proteins in breast tumor cells [79] whereas others have
found strong upregulation of the death receptors upon HDI
[92, 93]. In addition, HDIs can eﬃciently sensitize breast
cancer cells to TRAIL-mediated death signaling in vitro
and in preclinical in vivo models [77, 79, 94–96]a n dc a n
signiﬁcantly increase the apoptotic eﬀects of various drugs
targeting breast tumors.
HDIarealsoinvolved incelldiﬀerentiation. Forinstance,
Davis et al. showed that NaBu induced cell diﬀerentiation in
normal breast epithelial cell line as well as in breast cancer
cells as indicated by accumulation of lipid droplets [67].
Using valproic acid (VPA), Travaglini et al. conﬁrmed this
result by measuring milk lipid production in cell cultures
andshowedthatthiseﬀectwasindependentofthemammary
cells ER status [76].
The antiproliferative and proapoptotic eﬀects of HDIs
observed in vitro were conﬁrmed in preclinical mice or
rat breast cancer models [68, 95, 97, 98]. HDIs were
indeed shown to have anti-tumor activity in vivo,a l o n eo r
in combination with other therapies, by inhibiting tumor
growth or inducing tumor regression depending on the
models, and this was found for ERα-expressing [68]a sw e l l
as ERα-negative [98] breast tumor models. Interestingly,
Hirokawa et al. further showed that the class I-speciﬁc HDI
FK228 (depsipeptide or Istodax) was able to inhibit the
growth of tamoxifen-resistant MCF-7 xenografts in nude
mice(seebelowclinicalstudies)[97].Morerecently,Palmieri
et al. found that Vorinostat prevented the development of
brain metastasis using a preclinical model of triple-negative
breast cancer [99].
Taken together, these preclinical studies indicate that
HDI have anti-tumor eﬀects in breast cancer, targeting
ERα-positive and ER-negative cells as well as the most
aggressive mammary tumor types (tamoxifen-resistant and
triple-negative tumors).
4. Regulation of ER Expressionby HDACs
During the last decade, several groups have investigated the
mechanisms by which HDACs regulate ER expression in
breastcancercells.Thesestudies,whichmostlyconcernERα,
have highlighted the multiplicity of the regulations involved
(see Table 3 and Figure 1).
4.1. Negative Regulation of ERα Expression. In several ERα-
expressing human cancer cells from diﬀerent origin (breast,
endometrium, ovary...), treatment with HDAC inhibitors
such as trichostatin A (TSA), Vorinostat, FR901228, HC-
toxin, VPA, LBH589 (Panobinostat), or NaBu produced a
markeddecreaseinERαexpressionatthemRNAandprotein
levels, which is independent of the presence or absence of ER
ligands [82, 100, 101]. The mechanisms of this eﬀect seem to
involve diﬀerent types of regulation which take place both at
the transcriptional and posttranscriptional levels.
4.1.1. At the Transcriptional Level. A ﬁrst level of inhibition
of ERα expression takes place at the transcriptional level.
Indeed, several studies have reported a decrease in ERα
mRNA accumulation upon treatment with various HDAC
inhibitors [100–102]. Concomitant treatment by TSA and
cycloheximide, a protein synthesis inhibitor, did not aﬀect
the observed repression of ERα mRNA accumulation, sug-
gesting a direct role for HDAC activity in the maintenance of6 Journal of Biomedicine and Biotechnology
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Figure 1: HDAC and estrogen signaling. HDACs are involved in estrogen-genomic mechanisms mediated in part through estrogen response
element (ERE) targeting. ERα and numerous transcriptional coregulators (TCR) are acetylated proteins (acetyl mark is represented by a red
circle) which are substrates for HDAC. By removing acetyl marks, HDAC regulate the transcriptional activity of ERα.H D A C sa l s or e g u l a t e
the expression of ERα at the transcriptional level, in part through the control of MEF2 activity. They also modulate the level of ERα mRNA
by a mechanism which might involve miRNA expression. Finally, HDACs also regulate ERα stability, and one mechanism appears to involve
Hsp90 acetylation.
ERα transcription[73, 103]. Our unpublished data indicated
that the stability of ERα mRNA was not signiﬁcantly
modiﬁed in ERα-expressing MCF7 cells treated with TSA.
Transcription of the ERα gene is driven by several
diﬀerent promoters which span over 300kb (for a review,
see [104]). In MCF7 and Ishikawa cells, levels of transcripts
originating from promoters A, B, and C were all decreased
upon TSA treatment. In endometrial cells, this eﬀect was
associated with a reduction of the amount of acetylated H3
and H4 on the three promoters conﬁrming the inhibition of
their activity [103].
Interestingly, both HDAC5 and HDAC9 (class II
enzymes) have been shown to participate in the regulation of
the ERα promoter by repressing the activity of MEF2 [87].
A recent study also reported that inhibition of SIRT1 by
sirtinol or invalidation of the SIRT1 gene was associated with
ad e c r e a s eo fE R α expression in mammary cells which was
the consequence of a transcriptional regulation [91]. Finally,
several other HDACs could be involved in this negative
regulation since a reduction in ERα expression was observed
upon depletion of either HDAC1, HDAC2, or HDAC6 by
siRNA in T47D breast cancer cells [82]. In these cases, the
levels of regulation remain to be deﬁned.
4.1.2. Regulation of mRNA Stability. A regulation of ERα
mRNA expression could also take place at the posttran-
scriptional level since it has been reported that TSA when
administeredincombinationwith5-Aza2
 -deoxycytidine(5-
azadC or Dacogen) could decrease ERα mRNA stability
through altered subcellular localization of the RNA-binding
protein, HuR [105]. In addition, several miRNAs (miR-
206 for instance) have recently been reported to target
ERα mRNA (for a review, see [106]), and some of these
miRNAscouldbeHDIinducedandinvolvedinthedecreased
expression of ERα.
4.1.3. Regulation of Protein Stability. Several data support a
regulation at the posttranslational level. Results showing that
the MG132 inhibitor relieves the TSA-mediated decrease of
ERα accumulation ([102] and R. Margueron, unpublished
observations) provide evidence for a direct or indirect
involvement of the proteasome system in this regulation.
At the molecular level, one mechanism could involve the
Hsp90 chaperone complex which binds to and maintains
ERα in a ligand-binding conformation [107]a n dw h o s e
inhibition results in ubiquitin-mediated degradation of ERα
by the proteasome [108]. Indeed, the chaperone function
of Hsp90 has been shown to depend on HDAC activity,
and HDAC6-speciﬁc inhibition leads to hyperacetylation
of Hsp90, decreases its association with ERα,a n dr e s u l t s
in ERα ubiquitination and depletion [89]. Data reported
by Yi et al. conﬁrmed that inactivation of the heat shock
protein-90 (Hsp90) is involved in Vorinostat-induced ERα
degradation and that the ubiquitin ligase CHIP (C-terminal
Hsc70 interacting protein) enhances Vorinostat-induced
ERα degradation [109].
By contrast, a recent paper indicated that TSA-induced
acetylation of ERα in T47D cells was accompanied by an
increased stability of the ERα protein [110]. Interestingly, in
this study, overexpression of p300 also induced acetylation
and stability of ERα by blocking ubiquitination.
4.2. Reexpression of ERα in ER-Negative Cells. An interesting
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deals with data obtained in ERα-negative human breast
cancer cells. The group of N. E. Davidson initially reported
that treatment of such cells by TSA [111]o rV P A[ 112]
could lead to a dose- and time-dependent reexpression of
ERα mRNA. In addition, TSA [113] or Scriptaid (another
hydroxamic acid with HDI activity) [114] could potentiate
the eﬀect of DNA methyltransferase inhibitors such as 5-
azadC on the reexpression of the ERα protein.
In ERα-negative MDA-MB-231 cells, the silenced ERα
promoter has a repressive chromatin structure associ-
ated with DNA-methyltransferase 1 (DNMT1), DNMT3b,
HDAC1, and H3-K9 methylation [80, 115]. The molecular
mechanisms by which HDI reactivated silenced ERα gene in
MDA-MB-231 cells include chromatin structure reorganiza-
tion: for example, TSA induces acetylated histone H3 and
H4 but reduces HDAC1 and H3-K9 methylation at the ERα
promoter [80]. Chromatin immunoprecipitation analysis
showed that binding of TFAP2C to the ERα promoter was
blocked in ERα-negative cells, but that treatment with 5-
azadC/TSA enabled TFAP2C and polymerase II binding
[116].
IntheERα-negativehumanbreastcancercelllinesMDA-
MB-231 and MDA-MB-435, treatment with Panobinostat
at 100nM for 24 hours restored ERα mRNA and protein
expression without a concomitant demethylation of the ERα
promoter CpG island [117]. Importantly, the expression of
ERα mRNA was sustained at least 96 hours after withdrawal
of Panobinostat treatment. The same laboratory reported
that reexpression of ERα protein upon treatment with
Vorinostat,anotherpan-HDI,wascoupledwithlossofEGFR
in MDA-MB-231 cells, which overexpress EGFR [118].
4.3. Regulation of ERβ Expression. Fewer studies have
described the eﬀects of HDACs or HDAC inhibition on
ERβ expression in cancer cells. Recent studies reported the
upregulationofERβexpressioninovarian[119]andprostate
cancer cells at the mRNA and protein levels [120].
In breast cancer cells, HDI have been shown to clearly
increase ERβ expression at least at the transcriptional levels
in both ERα-negative [121]a n dE R α-positive cells [122].
Moreover, treatment with HDI was found to strongly
enhance the transcriptional activity of ERβ [121, 122].
According to Jang et al. [121], ERβ induction upon HDI
treatment could be involved in the sensitization of ERα-
negative breast cancer cells to hormonal therapy (see below).
5.Roles ofHDACsandHDIsinERSignaling
In addition to their role in the regulation of ER expression, a
large set of data also support a major role of HDACs in the
control of transcriptional signaling by estrogens (Table 3 and
Figure 1).
5.1. Several Components of the ER Signaling Pathway Are
Acetylated Proteins. Several types of posttranslational mod-
iﬁcations have been described as targeting nuclear receptor
(forareview,see[123])andcouldmodifyseveralparameters
such as DNA-binding activity, interactions with positive or
negative transcriptional regulators, and stability or subcel-
lular localization of the protein. It has also been shown
that ERα as other nuclear receptors could be modiﬁed at
the posttranslational level by addition of acetylated groups
on lysine residues [124, 125]. The group of Pestell initially
reported that ERα was acetylated in vitro by p300 on two
lysine residues located in the hinge region of the protein
[126]. Mutation of the two amino acids resulted in an
enhancement of hormone sensitivity, suggesting that acety-
lation normally decreases ligand response. More recently,
using a variety of biochemical and cell-based approaches,
Kim et al. identiﬁed two other lysines within ERα (K266
and K268) as primary targets of NCOA2-dependent p300
acetylation [127]. In this study, acetylation of these residues
increased DNA-binding activity of the receptor in gel shift
assay and ligand-dependent transactivation in transient
transfection experiments. It should be noted that K266/268
are not conserved in ERβ, and until now, acetylation of
this nuclear receptor has not been reported. Moreover, the
speciﬁc deacetylases which remove these marks are still
mostly unknown although preliminary data suggested that
both the NAD+-dependent SIRT1 enzyme or TSA sensitive
H D A Ca r ea b l et od e a c e t y l a t eE R α in vitro.
In addition to nuclear receptors themselves, several other
factors involved in estrogen signaling are acetyltransferase
substrates. Indeed, several nuclear receptor coregulators
such as ACTR/SRC3, SRC-1 and TIF2 [128], PGC1α [129],
RIP140/NRIP1 [130], or HDAC1 [131] are also modiﬁed by
acetylation, and this highlights the complexity of the eﬀects
resulting from the modulation of the acetylation balance in
response to HDAC inhibition (see below).
5.2. Direct and Indirect Recruitment of HDACs by ERs. Using
the chromatin immunoprecipitation technique (ChIP), the
presence of several HDACs has been detected on various ER-
target promoters. For instance, both HDAC1 and HDAC7
are present on the pS2 gene promoter region [84, 90]. In
the presence of partial antiestrogens such as tamoxifen or
raloxifen, HDAC2 and HDAC4 [85] or HDAC1 and HDAC3
[81] have been evidenced on the pS2 promoter or on other
estrogen target promoters such as the c-myc or cathepsin D
genes.
S e v e r a ls t u d i e sh a v er e p o r t e dd i ﬀerent modes of HDAC
recruitment by ERα. A direct association of HDAC1 with the
DNA binding and AF2 domains of ERα has been demon-
strated both by GST pull down and coimmunoprecipitation
[83]. A more recent study failed to conﬁrm this result, but
it described the in vitro interaction with class II HDAC5 and
9[ 87]. Finally, HDAC4 was shown to bind the N-terminal
A/B domain of ERα [86] and, more recently, the physical E2-
dependent association of HDAC6 with the AF2-domain of
ERα expressed as a fusion with a membrane targeting signal
was reported [88].
In addition to direct association with the receptor,
HDACs could also be indirectly recruited to target promot-
ers. Indeed, a huge number of ER transcription coregulators
which bind the receptor in the presence of agonists (for
instance RIP140 [132–134], SHP [135], and REA [136]) or
in the presence of antagonists (such as NCoR or SMRT8 Journal of Biomedicine and Biotechnology
[137, 138]) are able to recruit diﬀerent HDACs. This indirect
recruitment of HDACs belonging to the diﬀerent classes of
enzymes also increases the complexity of the relationship
between acetylation and estrogen signaling.
5.3. Role of HDACs in the Control of ER Transcriptional
Activity. As already mentioned, HDACs not only regulate
ER expression via intricate mechanisms but also participate
in the formation of ER transcriptional complexes. Diﬀerent
approaches, based on the modulation of their enzymatic
activity or their expression levels, have indeed investigated
whether or not they actively participate in the regulation of
estrogen transcriptional signaling.
5.3.1.EﬀectofHDACInhibitorsonERTranscriptionalActivity.
Using MCF-7 or HeLa cells transfected with an ERE-
containing luciferase reporter plasmid, we showed that
inhibition of HDAC activity increased transactivation of
both ERα and ERβ in the presence of agonist ligands [122].
In ERα-expressing cells, HDAC inhibitors also abolished the
transrepression ability of partial antiestrogens and increased
their agonist activity through a mechanism which requires
the reduction of ERα expression [100]. This eﬀect was not
obtained with class II selective inhibitors [74].
5.3.2. Class I HDAC. Very few data are available concerning
the role of class I HDACs in the control of ER activity. Kawai
et al. suggested that HDAC1 overexpression in 293T cells
suppresses the E2-dependent transcriptional activity of ERα
[83]. However, it is diﬃcult to ascertain that this eﬀect was
indeed due to a modulation of receptor transactivation and
not a simple reﬂect of a strong decrease in receptor levels.
Using a Knockdown strategy, it has been reported more
recently that selective depletion of HDAC2 in T47D cells
resulted in a decrease in PR levels but it is unclear whether
t h i si sd u et oam o d u l a t i o no fE R α activity [82].
5.3.3.ClassIIHDAC. ClassIIHDACshavealsobeendemon-
strated to act as important modulators of ERα activity. A
recent paper from the Olson’s laboratory has demonstrated a
role for HDAC5 and 9 in cardioprotection mediated by ERα
[87]. Upregulation of ERα signaling in female mice deleted
for either HDAC5 or -9 dramatically diminishes cardiac
dysfunction following myocardial infarction. This cardiac
protectionappearstobedue,atleastinpart,totheinduction
of neoangiogenesis in the infarcted region via upregulation
of the ER target gene Vascular Endothelial Growth Factor
(VEGF). These ﬁndings reveal a key role for MEF2 and class
II HDACs in the regulation of cardiac ER signaling and
the mechanisms underlying the cardioprotective eﬀects of
estrogen. Accordingly, van Rooij et al. showed that HDAC5
and HDAC9 repressed estrogen-dependent transcriptional
activation by ERα.
Another class II HDAC, HDAC7, seems to play a unique
role in E2-dependent repression of gene expression [90].
Indeed, in transient transfection experiments, increasing
concentrations of HDAC7 inhibited ERα activity in a dose-
dependent manner although the catalytic activity of HDAC7
did not appear to be required. More interestingly, knock-
down of HDAC7 using siRNA resulted in complete loss of E2
repression of diﬀerent target genes such as RPRM, CXCR4,
or NEDD9.
HDAC4 has also been shown to regulate transactivation
by ERα in the presence of either estradiol or antiestrogens
such as tamoxifen or raloxifen [86]. Overexpression or
silencing of HDAC4 impacted (negatively or positively) ERα
activity in a cell type-speciﬁc manner.
Finally, HDAC6 may also participates in rapid action of
estrogens (the so-called nongenomic action of ER), since
it has been proposed that upon estrogen stimulation, a
complex containing ERα and HDAC6 is rapidly translo-
cated at the membrane, where HDAC6 could functionally
interact with the microtubule network and cause tubulin
deacetylation [88]. However, analysis of E2-induced tubulin
deacetylation remains to be analyzed in HDAC6 knockdown
or knockout models.
5.3.4. Class III HDAC. A single study has investigated
whether class III HDACs play a role in the regulation of
ERα activity [91]. This work demonstrated that sirtinol,
an inhibitor of the SIRT1 deacetylase activity, inhibited
estrogen-dependent gene transcription in diﬀerent breast
cancer cell lines. This observation could be related to
previous data showing that the loss of SIRT1 expression in
female mice is associated with a defect in mammary gland
development [139].
6. Effects of HDIson HT Response
6.1. In Vitro Experiments
6.1.1. ERα-Positive Breast Tumors. As discussed brieﬂy in
Section 3, several HDIs have been shown to reverse acquired
hormone resistance in ERα-positive breast cancer cells lines.
For example, Hirokawa et al. showed that treatment of
tamoxifen sensitive and insensitive MCF-7 cells with dep-
sipeptide not only inhibited tumor cells proliferation in vitro
and in vivo but also abrogated tamoxifen-resistance. These
data suggest that HDIs could be useful for the treatment
of breast cancers which become resistant to currently used
estrogen antagonists such as tamoxifen [97]. Moreover,
Hodges-Gallagher et al. suggested that this resensitization
upon HDI, was not limited to tamoxifen, but could also be
observed with aromatase inhibitors [140]. The mechanisms
by which HDIs may reverse acquired hormone resistance in
ERα-positive breast tumor cells are probably complex and
may involve diﬀerent mechanisms according to tamoxifen or
antiaromatase treatments. For instance, inhibition of HDAC
enzymatic activity modulates ERα and ERβ expression
and may control the relative agonist activity of partial
antiestrogens (see above) [100]. Moreover, HDIs block the
activation of PAK1 [97] ,agr o wt hf a c t o rp a t h w a y ,w h i c hm a y
contribute to tamoxifen resistance [141]. In addition, De
Los Santos et al. showed that a combination of Vorinostat
and fulvestrant (a pure steroidal anti-estrogen also known
as ICI 182.780) was more potent than fulvestrant aloneJournal of Biomedicine and Biotechnology 9
to regulate the expression of cell cycle proteins, to induce
downregulation of ERα, and to decrease the transcription of
ERα target genes in MCF-7 breast cancer cells [75].
To our knowledge, no preclinical study has been pub-
lished evaluating the eﬀects of a treatment combining HDI
and HTs (tamoxifen or aromatase inhibitor) on the delay of
endocrine acquired resistance in ERα-positive breast cancer
cells or in xenografts.
6.1.2. ERα-Negative Breast Tumors. As stated in Section 1,
HTs are ineﬀective in ERα-negative breast carcinoma. Pre-
clinical studies have shown that ERα repression in these
tumors may be due to epigenetic modiﬁcations. The discov-
ery of HDACs recruitment in ERα gene promoter provides
a rationale for inhibiting HDACs activity to release ERα
transcriptional repression as a potential therapeutic strategy
(see Section 4). Several laboratories have reported that HDIs
could reverse hormone resistance in human ERα-negative
breast cancer cells. The combination of TSA and 5-azadC, a
DNMT inhibitor, restored sensitivity to tamoxifen in MDA-
MB 235 human breast cell lines and in nude mice. This
eﬀect was due to the reexpression of a functional ERα
and the level of tamoxifen growth suppression paralleled
that of ERα reexpression [98]. Similarly, restoration of
ERα expression by the pan HDI Panobinostat in MDA-
MB 231 cells enhanced sensitivity to 4-hydroxy-tamoxifen
(an active metabolite of tamoxifen)[ 117]. So, reexpression
of ERα might at least in part mediate the antiproliferative
eﬀect of tamoxifen, although other mechanisms are likely
to be involved. For instance, Jang et al. observed that
pretreatment of ERα-negative MDA-MB 231 and Hs578T
breast cancer cells with TSA alone could restore response
to tamoxifen whereas no apparent ERα could be detected
in the treated cells. The mechanism involved might be
linked to the upregulation of ERβ expression [121]. Other
mechanisms may involve modulation of growth signaling
pathways. Zhou et al. indeed showed that Panobinostat
allowed a decrease in EGFR expression together with the
suppression of EGF-initiated signaling pathways involved in
the loss of tamoxifen antiestrogenic eﬀect including phos-
phorylated PAK1, p38MAPK, and AKT [142]. Treatment of
ERα-negative and hormone resistant human breast cancer
cells MDA-MB 231 or xenografts with the HDI SNDX275
(MS275 or Entinostat) led to an upregulation of ERα and
aromatase expression. Importantly for clinical perspectives,
these up regulations resulted in a sensitization of MDA-MB
231 cells and xenografts to a treatment with an aromatase
inhibitor (Letrozole). The same authors reported inhibition
of growth, cell migration, and formation of micrometastasis
by treatment with Entinostat plus letrozole (Sabnis et al.,
communication at the San Antonio Breast Cancer Sympo-
sium 2009). Altogether, these results provide the basis of
therapies combining tamoxifen (or aromatase inhibitors)
and HDIs for the treatment of hormone refractory ERα-
negative breast cancer and open a new perspective for the
management of ERα-negative breast cancer.
6.2. Clinical Trials. Several HDIs have been used in clinical
trials for the treatment of hematological malignancies (with
great success in most studies) and for solid tumors although
with less impressive clinical eﬃcacy. Concerning breast
cancer, the HDIs Vorinostat, Panobinostat, and Entinostat
are currently being tested in patients with advanced and/or
metastatic disease. The most common adverse events of HDI
treatment include fatigue, nausea, diarrhea, thrombocytope-
nia, and lymphopenia [17, 18]. In metastatic breast cancers,
HDIs have limited eﬃcacy as single agents. For example, a
phase II study evaluating Vorinostat alone was stopped early
due to the absence of objective responses [143]. A phase
II study evaluating the eﬃcacy of Panobinostat alone in
HER2-negative women with locally recurrence or metastatic
breast cancer is still ongoing (NCI clinical trial protocol
NCT00777049; see http://www.cancer.gov/).
As stated above, HDIs as single agents have shown
limited activity in patients with solid tumor malignancies,
thus prompting clinicians to use these compounds in
combination with other therapies acting on other targets
than HDACs. Such drug combinations interfering with
both HDACs and growth factor pathways (HER2, EGFR,
BCR-ABL, etc.) have already shown promising anticancer
eﬀects in vitro [144–146]. Moreover, studies combining an
HDI with chemotherapy (Munster et al., communication
at the San Antonio Breast Cancer Symposium 2009) or
trastuzumab, an HER2 monoclonal antibody, (NCI clinical
trial NCT00567879) are ongoing. Preliminary results, in
heavily pretreated women who had either relapsed or
progressed during trastuzumab combined therapies proved
to be promising: Vorinostat or Panobinostat were indeed
shown to reverse trastuzumab resistance.
Since there is a good rationale for combining HDI with
HTs, several trials involving the combination of a pan-
or a selective HDI and an HT (tamoxifen, or aromatase
inhibitor) are ongoing (see Table 4). At the SABCS 2009,
Munster et al. reported preliminary results of a phase II
study, combining Vorinostat (400mg daily for 21 days of
28 days) and tamoxifen (20mg daily), in women with ER-
positive metastatic breast cancers whose tumor progressed
under aromatase inhibitors treatment. Moreover, patients
c o u l dh a v er e c e i v e du pt o3c h e m o t h e r a p yr e g i m e n sf o r
metastatic disease. In the ﬁrst 42 patients enrolled in this
trial, 34 were assessable for eﬃcacy to the date of the report:
7 (21%) had an objective response, and 4 (12%) had stable
disease for ≥6 months. These results are encouraging if
one considers that the expected response rate for tamoxifen
alone at this stage of disease is less than 10% and that
the trial of Luu et al., evaluating Vorinostat alone in
metastatic breast carcinoma reported no objective responses
[143].
Moreover, a preliminary phase II data suggest that
Entinostat, a class I selective HDI, may resensitize invasive
ER-positive breast cancer patients progressing under aro-
matase inhibitors although 80% of these patients had already
received tamoxifen (Yardley et al., communication at the
San Antonio Breast Cancer Symposium 2009). In metastatic
breastcarcinoma,additionaltrialsinvolvingthecombination
of an HDI including Vorinostat and Panobinostat with
aromatase inhibitors are underway.10 Journal of Biomedicine and Biotechnology
Table 4: Clinical trials combining HDI and HT in advanced/metastatic ER-positive breast carcinoma.
HDI HT Phase Patients Preliminary results Reference
Vorinostat (SAHA)
200mg twice daily
14d/21
Tam II AI resistant HR+
34 patients evaluated
21% OR
12% SD
Munster et al.
Poster # 6100
SABCS 2009
Entinostat
(SNDX275)
5m gw e e k l y
AI
(Exemestane) II AI resistant HR+
10 patients with >2
cycles
CB > 6m o n t h s( 1c a s e )
CB > 5m o n t h s( 2c a s e s )
NCI clinical trial
NCT00676663
Yardley et al.
Poster # 6111
SABCS 2009
Vorinostat (SAHA)
200mg twice daily
14d/21
AI
(anastrozole
letrozole, OR
exemestane)
II AI resistant Ongoing
NCI clinical trial
NCT01153672
Linden et al.
Panobinostat
(LBH589) once daily
on days 1, 3, 5 during
28d
AI
(Letrozole) I/II
HR−/+ (phase I)
triple-negative
disease (phase II)
Ongoing
NCI clinical trial
NCT01105312 Tan
et al.
Vorinostat (SAHA) Tam II
Stage I–III
(treatment for 2
weeks before
surgery)
Ongoing
NCI clinical trial
NCT01194427
Stearns et al.
AI: aromatase inhibitor. OR: objective response. SD: stable disease. CB: clinical beneﬁce. HR: hormone receptor. SABCS: San Antonio Breast Cancer
Symposium 2009.
7. PerspectivesandConclusions
In conclusion, analysis of the links between ERs and HDACs
underline multiple and intricate levels of interactions. Such
complexity is reﬂected in breast tumorigenesis as HDI have
opposite eﬀects on ERα expression in ER-positive and ER-
negative breast tumor cells. Several important questions
remain to be answered in order to further appreciate
these transcriptional and cellular crosstalks: what are the
roles of the diﬀerent HDAC isoforms? Do HDAC regulate
ER signaling independently of their catalytic activity? Are
sirtuins key players in these crosstalks? Do HDACs regulate
miRNA which target ER signaling? What is the exact role of
HDACs in hormone resistant breast tumors?
Despite these open questions, HDI in combination with
chemotherapies or hormonal therapies led to promising
results in the context of hormone-resistant breast cancers,
and several clinical trials are still ongoing in this ﬁeld.
Furtherstudiesareneededtodeﬁnethebestcombinationsof
HDI therapies for the most aggressive breast tumors and to
betterunderstandhowtheyimpacthormone-resistantbreast
cancers.
Moreover, as stated in this paper, much work is being
done today to deﬁne biomarkers that would identify which
tumors will better respond to HDI-combined treatments. In
the ﬁeld of breast cancer, it will certainly be important to
deﬁnebiomarkersforthereexpressionofERαinER-negative
tumors along with predictive biomarkers of anti-estrogen
sensitivity in hormone resistant tumors in response to HDI
treatments. Finally, few data have been performed on triple
negative breast tumors, which represent one of the most
aggressive groups of breast cancers or in the familial forms of
BRCA1 mutated tumors. The role of HDACs and the impact
of HDIs in these particular groups could possibly open new
therapeutic strategies.
References
[1] “Tamoxifen for early breast cancer: an overview of the
randomisedtrials.EarlyBreastCancerTrialists’Collaborative
Group,” Lancet, pp. 1451–1467, 1998.
[2] W.L.McGuire,K.B.Horwitz,O.H.Pearson,andA.Segaloﬀ,
“Current status of estrogen and progesterone receptors in
breast cancer,” Cancer, vol. 39, no. 6, pp. 2934–2947, 1977.
[3] V. J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne,
and G. M. Clark, “Progesterone receptor status signiﬁcantly
improves outcome prediction over estrogen receptor status
alone for adjuvant endocrine therapy in two large breast
cancer databases,” Journal of Clinical Oncology, vol. 21, no.
10, pp. 1973–1979, 2003.
[4] S. Massarweh and R. Schiﬀ, “Unraveling the mechanisms
of endocrine resistance in breast cancer: new therapeutic
opportunities,” Clinical Cancer Research, vol. 13, no. 7, pp.
1950–1954, 2007.
[ 5 ]R .B .R i g g i n s ,R .S .S c h r e c e n g o s t ,M .S .G u e r r e r o ,a n dA .H .
Bouton, “Pathways to tamoxifen resistance,” Cancer Letters,
vol. 256, no. 1, pp. 1–24, 2007.
[ 6 ] J .M .H o s k i n s ,L .A .C a r e y ,a n dH .L .M c L e o d ,“ C Y P 2 D 6a n d
tamoxifen: DNA matters in breast cancer,” Nature Reviews
Cancer, vol. 9, no. 8, pp. 576–586, 2009.
[7] N.Heldring,A.Pike,S.Anderssonetal.,“Estrogenreceptors:
how do they signal and what are their targets,” Physiological
Reviews, vol. 87, no. 3, pp. 905–931, 2007.
[8] X. J. Yang and E. Seto, “HATs and HDACs: from structure,
function and regulation to novel strategies for therapy and
prevention,” Oncogene, vol. 26, no. 37, pp. 5310–5318, 2007.Journal of Biomedicine and Biotechnology 11
[9] X. J. Yang and E. Seto, “The Rpd3/Hda1 family of lysine
deacetylases: from bacteria and yeast to mice and men,”
Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 206–
218, 2008.
[10] A. Vannini, C. Volpari, P. Gallinari, P. Jones, C. Steink¨ uhler,
and S. Di Marco, “Substrate binding to histone deacetylases
as shown by the crystal structure of the HDAC8-substrate
complex,” EMBO Reports, vol. 8, no. 9, pp. 879–884, 2007.
[11] A. Schuetz, J. Min, A. Allali-Hassani et al., “Human HDAC7
harbors a class IIa histone deacetylase-speciﬁc zinc binding
motif and cryptic deacetylase activity,” Journal of Biological
Chemistry, vol. 283, no. 17, pp. 11355–11363, 2008.
[12] R.Ficner,“NovelstructuralinsightsintoclassIandIIhistone
deacetylases,” Current Topics in Medicinal Chemistry, vol. 9,
no. 3, pp. 235–240, 2009.
[13] M. Haberland, R. L. Montgomery, and E. N. Olson, “The
many roles of histone deacetylases in development and
physiology: implications for disease and therapy,” Nature
Reviews Genetics, vol. 10, no. 1, pp. 32–42, 2009.
[ 1 4 ]O .W i t t ,H .E .D e u b z e r ,T .M i l d e ,a n dI .O e h m e ,“ H D A C
family: what are the cancer relevant targets?” Cancer Letters,
vol. 277, no. 1, pp. 8–21, 2009.
[15] W. Weichert, “HDAC expression and clinical prognosis in
humanmalignancies,”CancerLetters,vol.280,no.2,pp.168–
176, 2009.
[16] P. A. Marks and R. Breslow, “Dimethyl sulfoxide to vorino-
stat: development of this histone deacetylase inhibitor as an
anticancer drug,” Nature Biotechnology, vol. 25, no. 1, pp. 84–
90, 2007.
[17] J. Tan, S. Cang, Y. Ma, R. L. Petrillo, and D. Liu, “Novel
histone deacetylase inhibitors in clinical trials as anti-cancer
agents,” Journal of Hematology and Oncology, vol. 3, article
no. 5, 2010.
[18] S. Cang, Y. Ma, and D. Liu, “New clinical developments
in histone deacetylase inhibitors for epigenetic therapy of
cancer,” Journal of Hematology and Oncology, vol. 2, article
no. 22, 2009.
[19] T. Liu, S. Kuljaca, A. Tee, and G. M. Marshall, “Histone
deacetylase inhibitors: multifunctional anticancer agents,”
Cancer Treatment Reviews, vol. 32, no. 3, pp. 157–165, 2006.
[ 2 0 ]W .S .X u ,R .B .P a r m i g i a n i ,a n dP .A .M a r k s ,“ H i s t o n e
deacetylase inhibitors: molecular mechanisms of action,”
Oncogene, vol. 26, no. 37, pp. 5541–5552, 2007.
[ 2 1 ]J .E .B o l d e n ,M .J .P e a r t ,a n dR .W .J o h n s t o n e ,“ A n t i c a n c e r
activities of histone deacetylase inhibitors,” Nature Reviews
Drug Discovery, vol. 5, no. 9, pp. 769–784, 2006.
[22] S. Minucci and P. G. Pelicci, “Histone deacetylase inhibitors
and the promise of epigenetic (and more) treatments for
cancer,” Nature Reviews Cancer,vol.6,no.1,pp.38–51, 2006.
[23] S. Balasubramanian, E. Verner, and J. J. Buggy, “Isoform-
speciﬁc histone deacetylase inhibitors: the next step?” Cancer
Letters, vol. 280, no. 2, pp. 211–221, 2009.
[24] L.StimsonandN.B.LaThangue,“Biomarkersforpredicting
clinical responses to HDAC inhibitors,” Cancer Letters, vol.
280, no. 2, pp. 177–183, 2009.
[25] P. N. Munster, D. Marchion, S. Thomas et al., “Phase I
trial of vorinostat and doxorubicin in solid tumours: histone
deacetylase 2 expression as a predictive marker,” British
Journal of Cancer, vol. 101, no. 7, pp. 1044–1050, 2009.
[26] L. Ellis, Y. Pan, G. K. Smyth et al., “Histone deacetylase
inhibitor panobinostat induces clinical responses with asso-
ciated alterations in gene expression proﬁles in cutaneous T-
cell lymphoma,” Clinical Cancer Research, vol. 14, no. 14, pp.
4500–4510, 2008.
[27] O. Khan, S. Fotheringham, V. Wood et al., “HR23B is a
biomarker for tumor sensitivity to HDAC inhibitor-based
therapy,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 107, no. 14, pp. 6532–6537,
2010.
[28] J. Suzuki, Y. Y. Chen, G. K. Scott et al., “Protein acetylation
andhistonedeacetylaseexpressionassociatedwithmalignant
breast cancer progression,” Clinical Cancer Research, vol. 15,
no. 9, pp. 3163–3171, 2009.
[29] C. A. Krusche, P. Wulﬁng, C. Kersting et al., “Histone
deacetylase-1 and -3 protein expression in human breast
cancer: a tissue microarray analysis,” Breast Cancer Research
and Treatment, vol. 90, no. 1, pp. 15–23, 2005.
[30] Z. Zhang, H. Yamashita, T. Toyama et al., “Quantitation
of HDAC1 mRNA expression in invasive carcinoma of the
breast,” Breast Cancer Research and Treatment, vol. 94, no. 1,
pp. 11–16, 2005.
[ 3 1 ]X .H u ,H .M .S t e r n ,L .G ee ta l . ,“ G e n e t i ca l t e r a t i o n sa n d
oncogenic pathways associated with breast cancer subtypes,”
Molecular Cancer Research, vol. 7, no. 4, pp. 511–522, 2009.
[32] C. Sotiriou, P. Wirapati, S. Loi et al., “Gene expression
proﬁling in breast cancer: understanding the molecular basis
of histologic grade to improve prognosis,” Journal of the
National Cancer Institute, vol. 98, no. 4, pp. 262–272, 2006.
[33] L. H. Saal, P. Johansson, K. Holm et al., “Poor prognosis
in carcinoma is associated with a gene expression signature
of aberrant PTEN tumor suppressor pathway activity,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 104, no. 18, pp. 7564–7569, 2007.
[34] A. H. Bild, G. Yao, J. T. Chang et al., “Oncogenic pathway
signatures in human cancers as aguide to targeted therapies,”
Nature, vol. 439, no. 7074, pp. 353–357, 2006.
[35] K. Chin, S. DeVries, J. Fridlyand et al., “Genomic and
transcriptional aberrations linked to breast cancer patho-
physiologies,” Cancer Cell, vol. 10, no. 6, pp. 529–541, 2006.
[36] S. Gruvberger, M. Ringner, Y. Chen et al., “Estrogen receptor
status in breast cancer is associated with remarkably distinct
gene expression patterns,” Cancer Research, vol. 61, no. 16,
pp. 5979–5984, 2001.
[37] A. V. Ivshina, J. George, O. Senko et al., “Genetic reclassiﬁ-
cation of histologic grade delineates new clinical subtypes of
breast cancer,” Cancer Research, vol. 66, no. 21, pp. 10292–
10301, 2006.
[38] A.J.Minn,G.P.Gupta,P.M.Siegeletal.,“Genesthatmediate
breast cancer metastasis to lung,” Nature, vol. 436, no. 7050,
pp. 518–524, 2005.
[39] M. J. Van De Vijver, Y. D. He, L. J. Van ’T Veer et al., “A
gene-expression signature as a predictor of survival in breast
cancer,”NewEnglandJournalofMedicine,vol.347,no.25,pp.
1999–2009, 2002.
[ 4 0 ]Y .W a n g ,J .G .M .K l i j n ,Y .Z h a n ge ta l . ,“ G e n e - e x p r e s s i o n
proﬁles to predict distant metastasis of lymph-node-negative
primary breast cancer,” Lancet, vol. 365, no. 9460, pp. 671–
679, 2005.
[41] M. West, C. Blanchette, H. Dressman et al., “Predicting
the clinical status of human breast cancer by using gene
expression proﬁles,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 98, no. 20, pp.
11462–11467, 2001.
[42] K. Yu, K. Ganesan, L. D. Miller, and P. Tan, “A modular
analysis of breast cancer reveals a novel low-grade molecular
signature in estrogen receptor-positive tumors,” Clinical
Cancer Research, vol. 12, no. 11, pp. 3288–3296, 2006.12 Journal of Biomedicine and Biotechnology
[43] B. J. Boersma, M. Reimers, M. Yi et al., “A stromal
gene signature associated with inﬂammatory breast cancer,”
International Journal of Cancer, vol. 122, no. 6, pp. 1324–
1332, 2008.
[44] I. Hedenfalk, D. Duggan, Y. Chen et al., “Gene-expression
proﬁles in hereditary breast cancer,” New England Journal of
Medicine, vol. 344, no. 8, pp. 539–548, 2001.
[ 4 5 ]X .L u ,X .L u ,Z .C .W a n g ,J .D .I g l e h a r t ,X .Z h a n g ,a n dA .L .
Richardson, “Predicting features of breast cancer with gene
expression patterns,” Breast Cancer Research and Treatment,
vol. 108, no. 2, pp. 191–201, 2008.
[46] C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits
of human breast tumours,” Nature, vol. 406, no. 6797, pp.
747–752, 2000.
[47] A. L. Richardson, Z. C. Wang, A. De Nicolo et al., “X chro-
mosomal abnormalities in basal-like human breast cancer,”
Cancer Cell, vol. 9, no. 2, pp. 121–132, 2006.
[48] T. Sorlie, C. M. Perou, R. Tibshirani et al., “Gene expression
patterns of breast carcinomas distinguish tumor subclasses
with clinical implications,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98,
no. 19, pp. 10869–10874, 2001.
[49] J.R.Pollack,T.Sorlie,C.M.Perouetal.,“Microarrayanalysis
reveals a major direct role of DNA copy number alteration
in the transcriptional program of human breast tumors,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 20, pp. 12963–12968, 2002.
[50] T.Sorlie,R.Tibshirani,J.Parkeretal.,“Repeatedobservation
of breast tumor subtypes in independent gene expression
data sets,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 100, no. 14, pp. 8418–8423,
2003.
[51] C. Desmedt, F. Piette, S. Loi et al., “Strong time dependence
of the 76-gene prognostic signature for node-negative breast
cancer patients in the TRANSBIG multicenter independent
validation series,” Clinical Cancer Research, vol. 13, no. 11,
pp. 3207–3214, 2007.
[52] C. Ginestier, N. Cervera, P. Finetti et al., “Prognosis and
gene expression proﬁling of 20q13-ampliﬁed breast cancers,”
ClinicalCancerResearch,vol.12,no.15,pp.4533–4544,2006.
[53] K.R.Hess,K.Anderson,W.F.Symmansetal.,“Pharmacoge-
nomic predictor of sensitivity to preoperative chemotherapy
withpaclitaxelandﬂuorouracil,doxorubicin,andcyclophos-
phamide in breast cancer,” Journal of Clinical Oncology, vol.
24, no. 26, pp. 4236–4244, 2006.
[54] E. Huang, S. H. Cheng, H. Dressman et al., “Gene expression
predictors of breast cancer outcomes,” Lancet, vol. 361, no.
9369, pp. 1590–1596, 2003.
[55] P. M. Haverty, J. Fridlyand, L. Li et al., “High-resolution
genomic and expression analyses of copy number alterations
in breast tumors,” Genes Chromosomes and Cancer, vol. 47,
no. 6, pp. 530–542, 2008.
[56] P. K. Julka, R. T. Chacko, S. Nag et al., “A phase II study
of sequential neoadjuvant gemcitabine plus doxorubicin
followed by gemcitabine plus cisplatin in patients with oper-
able breast cancer: prediction of response using molecular
proﬁling,” British Journal of Cancer, vol. 98, no. 8, pp. 1327–
1335, 2008.
[ 5 7 ]C .S o t i r i o u ,S .Y .N e o ,L .M .M c S h a n ee ta l . ,“ B r e a s tc a n c e r
classiﬁcationandprognosisbasedongeneexpressionproﬁles
from a population-based study,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 18, pp. 10393–10398, 2003.
[58] H. Zhao, A. Langerod, Y. Ji et al., “Diﬀerent gene expression
patterns in invasive lobular and ductal carcinomas of the
breast,” Molecular Biology of the Cell, vol. 15, no. 6, pp. 2523–
2536, 2004.
[59] Z. Zhang, H. Yamashita, T. Toyama et al., “HDAC6 expres-
sion is correlated with better survival in breast cancer,”
ClinicalCancerResearch,vol.10,no.20,pp.6962–6968,2004.
[60] S. Saji, M. Kawakami, S. I. Hayashi et al., “Signiﬁcance of
HDAC6 regulation via estrogen signaling for cell motility
and prognosis in estrogen receptor-positive breast cancer,”
Oncogene, vol. 24, no. 28, pp. 4531–4539, 2005.
[61] S. F. Chin, A. E. Teschendorﬀ, J. C. Marioni et al., “High-
resolution aCGH and expression proﬁling identiﬁes a novel
genomic subtype of ER negative breast cancer,” Genome
Biology, vol. 8, no. 10, article no. R215, 2007.
[ 6 2 ]Y .N i k o l s k y ,E .S v i r i d o v ,J .Y a oe ta l . ,“ G e n o m e - w i d ef u n c -
tional synergy between ampliﬁed and mutated genes in
human breast cancer,” Cancer Research, vol. 68, no. 22, pp.
9532–9540, 2008.
[63] A. Inoue, N. Yoshida, Y. Omoto et al., “Development
of cDNA microarray for expression proﬁling of estrogen-
responsivegenes,”JournalofMolecularEndocrinology,vol.29,
no. 2, pp. 175–192, 2002.
[64] Y. S. Lee, K. H. Lim, X. Guo et al., “The cytoplasmic
deacetylase HDAC6 is required for eﬃcient oncogenic
tumorigenesis,” Cancer Research, vol. 68, no. 18, pp. 7561–
7569, 2008.
[65] N. Yoshida, Y. Omoto, A. Inoue et al., “Prediction of
prognosis of estrogen receptor-positive breast cancer with
combination of selected estrogen-regulated genes,” Cancer
Science, vol. 95, no. 6, pp. 496–502, 2004.
[66] C. L. Hanigan, M. van Engeland, A. P. De Bruine et al., “An
inactivating mutation in HDAC2 leads to dysregulation of
apoptosis mediated by APAF1,” Gastroenterology, vol. 135,
no. 5, pp. 1654–1664, 2008.
[67] T. Davis, C. Kennedy, Y. E. Chiew, C. L. Clarke, and A.
Defazio, “Histone deacetylase inhibitors decrease prolifer-
ation and modulate cell cycle gene expression in normal
mammary epithelial cells,” Clinical Cancer Research, vol. 6,
no. 11, pp. 4334–4342, 2000.
[68] D. M. Vigushin, S. Ali, P. E. Pace et al., “Trichostatin A is a
histone deacetylase inhibitor with potent antitumor activity
against breastcancer invivo,” ClinicalCancerResearch,vol.7,
no. 4, pp. 971–976, 2001.
[69] R. Margueron, V. Duong, A. Castet, and V. Cavailles,
“Histone deacetylase inhibition and estrogen signalling in
human breast cancer cells,” Biochemical Pharmacology, vol.
68, no. 6, pp. 1239–1246, 2004.
[70] R. Margueron, A. Licznar, G. Lazennec, F. Vignon, and
V. Cavailles, “Oestrogen receptor α increases p21/C gene
expression and the antiproliferative activity of histone
deacetylase inhibitors in human breast cancer cells,” Journal
of Endocrinology, vol. 179, no. 1, pp. 41–53, 2003.
[ 7 1 ]J .P .A l a o ,A .V .S t a v r o p o u l o u ,E .W .F .L a m ,R .C .C o o m b e s ,
and D. M. Vigushin, “Histone deacetylase inhibitor, Tricho-
statin A induces ubiquitin-dependent cyclin D1 degradation
inMCF-7breastcancercells,”MolecularCancer,vol.5,article
no. 8, 2006.
[72] M. Ocker and R. Schneider-Stock, “Histone deacetylase
inhibitors: signalling towards p21
cip1/waf1,” International Jour-
nal of Biochemistry and Cell Biology,v o l .3 9 ,n o .7 - 8 ,p p .
1367–1374, 2007.Journal of Biomedicine and Biotechnology 13
[73] J. P. Alao, E. W.-F. Lam, S. Ali et al., “Histone deacety-
lase inhibitor trichostatin A represses estrogen receptor α-
dependent transcription and promotes proteasomal degra-
dation of cyclin D1 in human breast carcinoma cell lines,”
ClinicalCancerResearch,vol.10,no.23,pp.8094–8104,2004.
[74] V.Duong,C.Bret,L.Altuccietal.,“SpeciﬁcactivityofclassII
histone deacetylases in human breast cancer cells,” Molecular
Cancer Research, vol. 6, no. 12, pp. 1908–1919, 2008.
[75] M. De Los Santos, O. Martinez-Iglesias, and A. Aranda,
“Anti-estrogenic actions of histone deacetylase inhibitors in
MCF-7breastcancercells,”Endocrine-RelatedCancer,vol.14,
no. 4, pp. 1021–1028, 2007.
[76] L. Travaglini, L. Vian, M. Billi, F. Grignani, and C. Nervi,
“Epigenetic reprogramming of breast cancer cells by valproic
acid occurs regardless of estrogen receptor status,” Interna-
tional Journal of Biochemistry and Cell Biology, vol. 41, no. 1,
pp. 225–234, 2009.
[77] L. Fuino, P. Bali, S. Wittmann et al., “Histone deacety-
lase inhibitor LAQ824 down-regulates Her-2 and sensitizes
human breast cancer cells to trastuzumab, taxotere, gemc-
itabine, and epothilone B,” Molecular Cancer Therapeutics,
vol. 2, no. 10, pp. 971–984, 2003.
[78] V. Chopin, R. A. Toillon, N. Jouy, and X. Le Bourhis, “P21
is dispensable for G1 arrest, but indispensable for apoptosis
induced by sodium butyrate in MCF-7 breast cancer cells,”
Oncogene, vol. 23, no. 1, pp. 21–29, 2004.
[79] P. Bali, M. Pranpat, R. Swaby et al., “Activity of suberoy-
lanilide hydroxamic acid against human breast cancer cells
with ampliﬁcation of Her-2,” Clinical Cancer Research, vol.
11, no. 17, pp. 6382–6389, 2005.
[ 8 0 ]D .S h a r m a ,J .B l u m ,X .Y a n g ,N .B e a u l i e u ,A .R .M a c l e o d ,
andN.E.Davidson,“ReleaseofmethylCpGbindingproteins
and histone deacetylase 1 from the estrogen receptor α (ER)
promoter upon reactivation in ER-negative human breast
cancer cells,” Molecular Endocrinology, vol. 19, no. 7, pp.
1740–1751, 2005.
[81] X. F. Liu and M. K. Bagchi, “Recruitment of distinct
chromatin-modifying complexes by tamoxifen-complexed
estrogen receptor at natural target gene promoters in vivo,”
Journal of Biological Chemistry, vol. 279, no. 15, pp. 15050–
15058, 2004.
[82] E. Bic ¸aku, D. C. Marchion, M. L. Schmitt, and P. N. Munster,
“Selective inhibition of histone deacetylase 2 silences proges-
teronereceptor-mediatedsignaling,”CancerResearch,vol.68,
no. 5, pp. 1513–1519, 2008.
[83] H. Kawai, H. Li, S. Avraham, S. Jiang, and H. K. Avraham,
“Overexpression of histone deacetylase HDAC1 modulates
breast cancer progression by negative regulation of estrogen
receptor α,” International Journal of Cancer, vol. 107, no. 3,
pp. 353–358, 2003.
[ 8 4 ] R .M e t i v i e r ,G .P e n o t ,M .R .H u b n e re ta l . ,“ E s t r o -
gen receptor-α directs ordered, cyclical, and combinatorial
recruitment of cofactors on a natural target promoter,” Cell,
vol. 115, no. 6, pp. 751–763, 2003.
[85] Y. Shang and M. Brown, “Molecular determinants for the
tissue speciﬁcity of SERMs,” Science, vol. 295, no. 5564, pp.
2465–2468, 2002.
[86] H. Leong, J. R. Sloan, P. D. Nash, and G. L. Greene,
“Recruitment of histone deacetylase 4 to the N-terminal
region of estrogen receptor α,” Molecular Endocrinology, vol.
19, no. 12, pp. 2930–2942, 2005.
[ 8 7 ]E .V a nR o o i j ,J .F i e l i t z ,L .B .S u t h e r l a n de ta l . ,“ M y o c y t e
enhancer factor 2 and class ii histone deacetylases control a
gender-speciﬁc pathway of cardioprotection mediated by the
estrogen receptor,” Circulation Research, vol. 106, no. 1, pp.
155–165, 2010.
[88] K. Azuma, T. Urano, K. Horie-Inoue et al., “Association
of estrogen receptor a and histone deacetylase 6 causes
rapid deacetylation of tubulin in breast cancer cells,” Cancer
Research, vol. 69, no. 7, pp. 2935–2940, 2009.
[89] W. Fiskus, Y. Ren, A. Mohapatra et al., “Hydroxamic acid
analogue histone deacetylase inhibitors attenuate estrogen
receptor-α levels and transcriptional activity: a result of
hyperacetylation and inhibition of chaperone function of
heat shock protein 90,” Clinical Cancer Research, vol. 13, no.
16, pp. 4882–4890, 2007.
[90] S. Malik, S. Jiang, J. P. Garee et al., “Histone deacetylase 7 and
FoxA1 in estrogen-mediated repression of RPRM,” Molecular
and Cellular Biology, vol. 30, no. 2, pp. 399–412, 2010.
[91] Y.Yao,H.Li,Y.Gu,N.E.Davidson,andQ.Zhou,“Inhibition
of SIRT1 deacetylase suppresses estrogen receptor signaling,”
Carcinogenesis, vol. 31, no. 3, pp. 382–387, 2009.
[92] V. Chopin, C. Slomianny, H. Hondermarck, and X. Le
Bourhis, “Synergistic induction of apoptosis in breast cancer
cells by cotreatment with butyrate and TNF-alpha, TRAIL,
or anti-Fas agonist antibody involves enhancement of death
receptors’ signaling and requires P21
waf1,” Experimental Cell
Research, vol. 298, no. 2, pp. 560–573, 2004.
[93] S. Nakata, T. Yoshida, M. Horinaka, T. Shiraishi, M. Wakada,
and T. Sakai, “Histone deacetylase inhibitors upregulate
death receptor 5/TRAIL-R2 and sensitize apoptosis induced
by TRAIL/APO2-L in human malignant tumor cells,” Onco-
gene, vol. 23, no. 37, pp. 6261–6271, 2004.
[94] T. R. Singh, S. Shankar, and R. K. Srivastava, “HDAC
inhibitors enhance the apoptosis-inducing potential of
TRAIL in breast carcinoma,” Oncogene, vol. 24, no. 29, pp.
4609–4623, 2005.
[95] A.J.Frew,R.K.Lindemann,B.P.Martinetal.,“Combination
therapy of established cancer using a histone deacetylase
inhibitor and a TRAIL receptor agonist,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 105, no. 32, pp. 11317–11322, 2008.
[96] S. Shankar, R. Davis, K. P. Singh, R. Kurzrock, D. D.
Ross, and R. K. Srivastava, “Suberoylanilide hydroxamic
acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast
cancer cells orthotopically implanted in BALB/c nude mice,”
Molecular Cancer Therapeutics, vol. 8, no. 6, pp. 1596–1605,
2009.
[97] Y. Hirokawa, M. Arnold, H. Nakajima, J. Zalcberg, and H.
Maruta, “Signal therapy of breast cancers by the HDAC
inhibitor FK228 that blocks the activation of PAK1 and
abrogates the tamoxifen-resistance,” Cancer Biology and
Therapy, vol. 4, no. 9, pp. 956–960, 2005.
[98] J. Fan, W. J. Yin, J. S. Lu et al., “ERα negative breast cancer
cells restore response to endocrine therapy by combination
treatment with both HDAC inhibitor and DNMT inhibitor,”
JournalofCancerResearchandClinicalOncology,vol.134,no.
8, pp. 883–890, 2008.
[ 9 9 ]D .P a l m i e r i ,P .R .L o c k m a n ,F .C .T h o m a se ta l . ,“ V o r i n o s t a t
inhibits brain metastatic colonization in a model of triple-
negative breast cancer and induces DNA double-strand
breaks,” Clinical Cancer Research, vol. 15, no. 19, pp. 6148–
6157, 2009.
[100] R. Margueron, V. Duong, S. Bonnet et al., “Histone deacety-
lase inhibition and estrogen receptor α levels modulate the
transcriptional activity of partial antiestrogens,” Journal of
Molecular Endocrinology, vol. 32, no. 2, pp. 583–594, 2004.14 Journal of Biomedicine and Biotechnology
[101] A. DeFazio, Y. E. Chiew, C. Donoghue, C. S. L. Lee, and
R. L. Sutherland, “Eﬀect of sodium butyrate on estrogen
receptor and epidermal growth factor receptor gene expres-
sion in human breast cancer cell lines,” Journal of Biological
Chemistry, vol. 267, no. 25, pp. 18008–18012, 1992.
[102] G. Reid, R. Metivier, C. Y. Lin et al., “Multiple mecha-
nisms induce transcriptional silencing of a subset of genes,
including oestrogen receptor α, in response to deacetylase
inhibitionbyvalproicacidandtrichostatinA,”Oncogene,vol.
24, no. 31, pp. 4894–4907, 2005.
[103] W.Rocha,R.Sanchez, J.Deschenes etal.,“Oppositeeﬀectsof
histonedeacetylaseinhibitorsonglucocorticoidandestrogen
signaling in human endometrial ishikawa cells,” Molecular
Pharmacology, vol. 68, no. 6, pp. 1852–1862, 2005.
[104] M. Kos, G. Reid, S. Denger, and F. Gannon, “Minireview:
genomic organization of the human ERα gene promoter
region,” Molecular Endocrinology, vol. 15, no. 12, pp. 2057–
2063, 2001.
[105] P. Pryzbylkowski, O. Obajimi, and J. C. Keen, “Trichostatin
Aa n d5A z a - 2   deoxycytidine decrease estrogen receptor
mRNA stability in ER positive MCF7 cells through modula-
tion of HuR,” Breast Cancer Research and Treatment, vol. 111,
no. 1, pp. 15–25, 2008.
[106] C.M.Klinge,“EstrogenregulationofmicroRNAexpression,”
Current Genomics, vol. 10, no. 3, pp. 169–183, 2009.
[107] A. E. Fliss, S. Benzeno, J. Rao, and A. J. Caplan, “Control of
estrogenreceptorligandbindingbyHsp90,”JournalofSteroid
Biochemistry and Molecular Biology, vol. 72, no. 5, pp. 223–
230, 2000.
[108] L.WhitesellandS.L.Lindquist,“HSP90andthechaperoning
ofcancer,”Nature Reviews Cancer,vol.5,no.10,pp.761–772,
2005.
[109] X. Yi, W. Wei, S. Y. Wang, Z. Y. Du, Y. J. Xu, and
X. D. Yu, “Histone deacetylase inhibitor SAHA induces
ERα degradation in breast cancer MCF-7 cells by CHIP-
mediated ubiquitin pathway and inhibits survival signaling,”
Biochemical Pharmacology, vol. 75, no. 9, pp. 1697–1705,
2008.
[110] S. H. Kim, H. J. Kang, H. Na, and M. O. Lee, “Trichostatin
A enhances acetylation as well as protein stability of ERalpha
through induction of p300 protein,” Breast Cancer Research,
vol. 12, no. 2. article no. R22, 2010.
[111] X. Yang, A. T. Ferguson, S. J. Nass et al., “Transcriptional
activation of estrogen receptor α in human breast cancer cells
by histone deacetylase inhibition,” Cancer Research, vol. 60,
no. 24, pp. 6890–6894, 2000.
[112] N. Fortunati, S. Bertino, L. Costantino et al., “Valproic acid
restores ERα and antiestrogen sensitivity to ERα-negative
breast cancer cells,” Molecular and Cellular Endocrinology,
vol. 314, no. 1, pp. 17–22, 2010.
[113] X. Yang, D. L. Phillips, A. T. Ferguson, W. G. Nelson, J. G.
Herman,andN.E.Davidson,“Synergisticactivationoffunc-
tional estrogen receptor (ER)-α by DNA methyltransferase
and histone deacetylase inhibition in human ER-α-negative
breastcancercells,”CancerResearch,vol.61,no.19,pp.7025–
7029, 2001.
[114] J.C.Keen,L.Yan,K.M.Macketal.,“Anovelhistonedeacety-
lase inhibitor, Scriptaid, enhances expression of functional
estrogen receptor α (ER) in ER negative human breast cancer
cells in combination with 5-aza 2 -deoxycytidine,” Breast
Cancer Research and Treatment, vol. 81, no. 3, pp. 177–186,
2003.
[115] M. Macaluso, C. Cinti, G. Russo, A. Russo, and A. Giordano,
“pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/
p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular
complexes mediate the transcription of estrogen receptor-α
in breast cancer,” Oncogene, vol. 22, no. 23, pp. 3511–3517,
2003.
[116] G. W. Woodﬁeld, M. J. Hitchler, Y. Chen, F. E. Domann,
a n dR .J .W e i g e l ,“ I n t e r a c t i o no fT F A P 2 Cw i t ht h ee s t r o g e n
receptor-α promoter is controlled by chromatin structure,”
ClinicalCancerResearch,vol.15,no.11,pp.3672–3679,2009.
[117] Q. Zhou, P. Atadja, and N. E. Davidson, “Histone deacetylase
inhibitor LBH589 reactivates silenced estrogen receptor
alpha (ER) gene expression without loss of DNA hyperme-
thylation,” Cancer Biology and Therapy, vol. 6, no. 1, pp. 64–
69, 2007.
[118] Q. Zhou, P. G. Shaw, and N. E. Davidson, “Inhibition of
histone deacetylase suppresses EGF signaling pathways by
destabilizing EGFR mRNA in ER-negative human breast
cancer cells,” Breast Cancer Research and Treatment, vol. 117,
no. 2, pp. 443–451, 2009.
[119] O. I. W. S. Yap, G. Bhat, L. Liu, and T. O. Tollefsbol,
“Epigenetic modiﬁcations of the estrogen receptor β gene in
epithelial ovarian cancer cells,” Anticancer Research, vol. 29,
no. 1, pp. 139–144, 2009.
[120] T. J. Walton, G. Li, R. Seth, S. E. McArdle, M. C. Bishop, and
R. C. Rees, “DNA demethylation and histone deacetylation
inhibition co-operate to re-express estrogen receptor beta
and induce apoptosis in prostate cancer cell-lines,” Prostate,
vol. 68, no. 2, pp. 210–222, 2008.
[121] E. R. Jang, S. J. Lim, E. S. Lee et al., “The histone deacety-
lase inhibitor trichostatin a sensitizes estrogen receptor α-
negative breast cancer cells to tamoxifen,” Oncogene, vol. 23,
no. 9, pp. 1724–1736, 2004.
[122] V. Duong, A. Licznar, R. Margueron et al., “ERα and
ERβ expression and transcriptional activity are diﬀerentially
regulated by HDAC inhibitors,” Oncogene, vol. 25, no. 12, pp.
1799–1806, 2006.
[123] H. Faus and B. Haendler, “Post-translational modiﬁcations
of steroid receptors,” Biomedicine and Pharmacotherapy, vol.
60, no. 9, pp. 520–528, 2006.
[124] M. Fu, C. Wang, A. T. Reutens et al., “p300 and p300/cAMP-
response element-binding protein-associated factor acety-
late the androgen receptor at sites governing hormone-
dependent transactivation,” Journal of Biological Chemistry,
vol. 275, no. 27, pp. 20853–20860, 2000.
[125] A. L. Jacob, J. Lund, P. Martinez, and L. Hedin, “Acetylation
of steroidogenic factor 1 protein regulates its transcriptional
activity and recruits the coactivator GCN5,” Journal of
BiologicalChemistry,vol.276,no.40,pp.37659–37664,2001.
[126] C. Wang, M. Fu, R. H. Angeletti et al., “Direct acetylation
of the estrogen receptor alpha hinge region by p300 regulates
transactivationandhormonesensitivity,”JournalofBiological
Chemistry, vol. 276, no. 21, pp. 18375–18383, 2001.
[127] Y. M. Kim, E. M. Woo, Y. T. E. Chong, D. R. Homenko,
and W. L. Kraus, “Acetylation of estrogen receptor α by
p300 at lysines 266 and 268 enhances the deoxyribonucleic
acid binding and transactivation activities of the receptor,”
Molecular Endocrinology, vol. 20, no. 7, pp. 1479–1493, 2006.
[128] H. Chen, R. J. Lin, W. Xie, D. Wilpitz, and R. M. Evans,
“Regulation of hormone-induced histone hyperacetylation
and gene activation via acetylation of an acetylase,” Cell, vol.
98, no. 5, pp. 675–686, 1999.Journal of Biomedicine and Biotechnology 15
[129] C. Lerin, J. T. Rodgers, D. E. Kalume, S. H. Kim, A. Pandey,
and P. Puigserver, “GCN5 acetyltransferase complex controls
glucose metabolism through transcriptional repression of
PGC-1α,” Cell Metabolism, vol. 3, no. 6, pp. 429–438, 2006.
[130] N. Vo, C. Fjeld, and R. H. Goodman, “Acetylation of
nuclear hormone receptor-interacting protein RIP140 reg-
ulates binding of the transcriptional corepressor CtBP,”
MolecularandCellularBiology,vol.21,no.18,pp.6181–6188,
2001.
[131] Y. Qiu, Y. Zhao, M. Becker et al., “HDAC1 acetylation is
linked to progressive modulation of steroid receptor-induced
gene transcription,” Molecular Cell, vol. 22, no. 5, pp. 669–
679, 2006.
[132] A. Castet, A. Boulahtouf, G. Versini et al., “Multiple domains
of the receptor-interacting protein 140 contribute to tran-
scription inhibition,” Nucleic Acids Research, vol. 32, no. 6,
pp. 1957–1966, 2004.
[133] M. Christian, J. M. A. Tullet, and M. G. Parker, “Charac-
terization of four autonomous repression domains in the
corepressor receptor interacting protein 140,” Journal of
BiologicalChemistry,vol.279,no.15,pp.15645–15651,2004.
[134] LI. N. Wei, M. Farooqui, and X. Hu, “Ligand-dependent
formation of retinoid receptors, receptor-interacting protein
140 (RIP140), and histone deacetylase complex is mediated
by a novel receptor-interacting motif of RIP140,” Journal of
BiologicalChemistry,vol.276,no.19,pp.16107–16112,2001.
[135] J.Gobinet,S.Carascossa,V.Cavailles,F.Vignon,J.C.Nicolas,
and S. Jalaguier, “SHP represses transcriptional activity via
recruitment of histone deacetylases,” Biochemistry, vol. 44,
no. 16, pp. 6312–6320, 2005.
[136] V. Kurtev, R. Margueron, K. Kroboth, E. Ogris, V. Cavailles,
and C. Seiser, “Transcriptional regulation by the repressor
of estrogen receptor activity via recruitment of histone
deacetylases,”JournalofBiologicalChemistry,vol.279,no.23,
pp. 24834–24843, 2004.
[137] J.Li,J.Wang,J.Wangetal.,“BothcorepressorproteinsSMRT
and N-CoR exist in large protein complexes containing
HDAC3,” EMBO Journal, vol. 19, no. 16, pp. 4342–4350,
2000.
[138] M. G. Guenther, O. Barak, and M. A. Lazar, “The SMRT
and N-CoR corepressors are activating cofactors for histone
deacetylase 3,” Molecular and Cellular Biology, vol. 21, no. 18,
pp. 6091–6101, 2001.
[139] H. Li, G. K. Rajendran, N. Liu, C. Ware, B. P. Rubin, and
Y. Gu, “SirT1 modulates the estrogen-insulin-like growth
factor-1 signaling for postnatal development of mammary
gland in mice,” Breast Cancer Research, vol. 9, no. 1, article
no. R1, 2007.
[140] L. Hodges-Gallagher, C. D. Valentine, S. E. Bader, and P.
J. Kushner, “Estrogen receptor beta increases the eﬃcacy of
antiestrogensbyeﬀectsonapoptosisandcellcyclinginbreast
cancer cells,” Breast Cancer Research and Treatment, vol. 109,
no. 2, pp. 241–250, 2008.
[141] S. K. Rayala, A. H. Talukder, S. Balasenthil et al., “P21-
activated kinase 1 regulation of estrogen receptor-α activa-
tion involves serine 305 activation linked with serine 118
phosphorylation,” Cancer Research, vol. 66, no. 3, pp. 1694–
1701, 2006.
[142] Q. Zhou, P. G. Shaw, and N. E. Davidson, “Inhibition of
histone deacetylase suppresses EGF signaling pathways by
destabilizing EGFR mRNA in ER-negative human breast
cancer cells,” Breast Cancer Research and Treatment, vol. 117,
no. 2, pp. 443–451, 2009.
[143] T. H. Luu, R. J. Morgan, L. Leong et al., “A phase II trial of
vorinostat (suberoylanilide hydroxamic acid) in metastatic
breast cancer: a California cancer consortium study,” Clinical
Cancer Research, vol. 14, no. 21, pp. 7138–7142, 2008.
[144] C. J. Lai, R. Bao, XU. Tao et al., “CUDC-101, a multitargeted
inhibitor of histone deacetylase, epidermal growth factor
receptor, and human epidermal growth factor receptor 2,
exerts potent anticancer activity,” Cancer Research, vol. 70,
no. 9, pp. 3647–3656, 2010.
[145] S. Mahboobi, S. Dove, A. Sellmer et al., “Design of chimeric
histone deacetylase- and tyrosine kinase-inhibitors: a series
of Imatinib hybrides as potent Inhibitors of wild-type and
mutant BCR-ABL, PDGF-Rβ, and histone deacetylases,”
Journal of Medicinal Chemistry, vol. 52, no. 8, pp. 2265–2279,
2009.
[146] X. Cai, H. X. Zhai, J. Wang et al., “Discovery of 7-(4-(3-
Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-
hydroxyheptanamide (CUDC-101) as a potent multi-acting
HDAC, EGFR, and HER2 inhibitor for the treatment of
cancer,” Journal of Medicinal Chemistry,v o l .5 3 ,n o .5 ,p p .
2000–2009, 2010.